Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. by Rosen, A. et al.
Br. J. Cancer (1993), 68, 605 609
c. 1993
Primary carcinoma of the Fallopian tube - a retrospective analysis of 115
patients
A. Rosen', M. Klein2, M. Lahousen3, A.H. Graf4, A. Rainer' & N. Vavra6 for the Austrian
Cooperative Study Group for Fallopian Tube Carcinoma7'8
'Department ofObstetrics and Gynecology, SMZ-Ost Vienna; 2Department ofObstetrics and Gynecoloyg, Hanusch Medical
Centre; 3Department ofObstetrics and Gynecology, University ofGrax; 4Department ofObstetrics andGynecology, Salzburg;
5Department ofPathology, University of Vienna; 6Department ofObstetrics and Gynecology, University of Vienna, Vienna,
Austria.
Summary Incidence and prognostic factors of primary carcinoma of the Fallopian tube were studied in a
retrospective multi-centre analysis of 115 women during the period 1980 to 1990. Data of 28 departments
(univesity as well as general hospitals) were included in the present study which was designed to evaluate the
current diagnosis and treatment of carcinoma of the Fallopian tube in Austria, and to compare the results
with those from the literature.
Stages were classified according to the modified FIGO-system for ovarian cancer; grading followed the
criteria of Hu et al. (1950).
The mean age of the patients was 62.5 years. Forty-seven (40.9%) tumours were found to be in stage I, 20
(17.4%) in stage II, 34 (29.6%) in stage III, and 14 (12.1%) in stage IV. In 82 patients, the tumour could be
completely removed. The surgical method applied in 95 cases was removal of the uterus, the adnexa, and/or
the omentum, or lymph nodes. Postoperatively patients underwent adjuvant therapy which was either
irradiation (n=40; 34.8%), or chemotherapy (n=49; 42.6%); 26 women (22.6%) had no therapy after
operation. The 5-year survival rate for all stages was 36.5%. In stages I and II the 5-year survival was 50.8%
compared to 13.6% in stages III and IV.
FIGO-stage I and II and a residual tumour less than 2cm in advanced disease had a prognostically
favourable impact, which was proven in univariate as well as multivariate analysis.
Primary carcinoma of the Fallopian tubes is a very rare, but
highly aggressive tumour. Worldwide, little more than 1,500
cases have been published (Pfleiderer, 1984). Renaud describ-
ed the disease as early as 1847 (Renaud & Ricci, 1945), and
Rokitansky in 1861, yet Orthmann (1886, 1888) was the first
to mention carcinoma of the Fallopian tube as a pathologic
entity in 1866. The most extensive documentation on car-
cinoma of the Fallopian tube was published by Niirnberger
in 1932.
The incidence of carcinoma of the Fallopian tube among
the neoplasms of the female genital tract varies between 0.15
and 1.8% (Hanton et al., 1966; Sedlis, 1969; Dodson et al.,
1970; Engeler et al., 1981). A Danish study reports an inci-
dence of 0.29 out of 100,000 women (Pfeiffer et al., 1989).
From 1980 onwards, cancer of the tuba uterina has been
requested by the Cancer Registry of the Austrian Central
Statistical Office. During the period from 1980 to 1990, a
total of 213 cases was reported in Austria; the annual distri-
bution is given in Table I.
There is a peak incidence in higher age groups. On average
the disease occurs within the sixth decennium of life (Engeler
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et al., 1981). Despite the characteristic triad of clinical symp-
toms, vaginal haemorrhage, leukorrhoea and abdominal
pain, laparotomy is often performed on account of an unde-
fined abdominal tumour (Bohme et al., 1992; Kubista &
Kubka, 1977).
The recurring discharge, a serous fluid amber to reddish in
colour, is pathognomonic. It occurs extremely rarely and
therefore is often misinterpreted (Niirnberger, 1932; Sedlis,
1969; Benedet & White, 1981). For these reasons, primary
carcinoma of the Fallopian tube is in fact diagnosed intra-
operatively or most often histologically (Jones, 1965; Eddy et
al., 1984).
The low number of cases, heterogeneous staging system
and different methods of treatment, particularly as far as
postoperative therapy is concerned, make it difficult to com-
pare results of different authors. Due to the rarity of the
disease a review of the available literature does not offer any
valid information regarding the distribution of prognostic
factors or the value of different treatment modalities for this
disease. Since experiences of single institutions are limited by
the small number ofpatients it was decided to start a nation-
wide, multicentric analysis.
The aim of this study was to summarise the current
methods of diagnosis and therapy in cases of primary car-
cinoma of the Fallopian tube in Austria.
Table I Annual incidence of Fallopian
1980- 1990
tube cancer in Austria
1980 17
1981 17
1982 20
1983 24
1984 23
1985 22
1986 8
1987 20
1988 27
1989 17
1990 18
Source: Austrian Cancer Registry.
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Materials and methods
Twenty-eight institutions of gynaecology and obstetrics, and
their associated departments of pathology, conducted a
nationwide retrospective, multicentre analysis in Austria. All
institutions received standardised computer-questionnaires
which were analysed centrally by the first authors (A.C.R.).
The study included all prognostic data, surgical as well as
postoperative therapies, and the patients' follow-up from
1980 to 1992, until the key-date October 1st.
A modified FIGO-classification was applied to stage
tumours (Table II). Histologic evaluation and grading follow-
ed the criteria of Hu et al. (1950): the main tumour is located
in the tube, arising from tubal epithelium. There is evidence
of a transitional zone between epithelium and malignant
epitheloid cells. Ovaries and uterus respectively exhibit nor-
mal epithelial cover or a lesser degree of tumour growth than
the tubes.
The participating departments provided the study centre
with histologic specimens which were evaluated by an inde-
pendent pathologist (A.R.) for grading and histologic type.
Furthermore the presence of ascites and the size of a
residual tumour after surgical removal of the cancer were
evaluated for their prognostic impact.
The results expressed as percentage were subjected to a
chi-square-test. Survival curves were obtained by the Kaplan-
Meier method, and the median survival times compared by
the Mantel-Cox log-rank test (Kaplan & Meier, 1958;
Mantel, 1986; Cox, 1972). Values of P<0.05 were con-
sidered to be statistically significant.
The Cox regression method was used in multivariate sur-
vival analysis to identify a combination of factors that
significantly impacted on survival (Cox, 1972). Independent
variables were identified as those factors chosen which had
reached statistical significance or at least a statistical trend in
the univariate analysis.
Wherever feasible, hazard plots were performed to assess
the appropriateness of the proportional hazards assumption
that underlies the Cox regression model. Log-likelihood ratio
test was used to determine the significance of factor combina-
tions.
Results
A total of 115 cases of primary cancer of the Fallopian tube
were included into the study. The mean age of the patients
was about 62.5 years, ranging from 37.3 to 82.0 years. In 47
Table II Staging for carcinoma of the Fallopian Tube FIGO-
Committee recommendation Singapore 13th September 1991
0 Carcinoma in situ (limited to tubal muscosa)
IA Unilateral tumour extension into the submucosa and/or
muscularis but not penetrating the serosal surface
IB Bilateral tumour extension
IC Bilateral tumour extension and positive malignant
washings
IIA Tumour extension or metastasis to pelvic peritoneum
IIB Tumour extension or metastasis to uterus and/or ovaries
IIC Tumour extension or metastasis to pelvic peritoneum and/
or uterus and/or ovaries and positive malignant
washings
IIIA Microscopic tumour extension to upper abdominal
peritoneum, small bowell or omentum; positive
malignant washings
IIIB Gross tumour extension to upper abdominal peritoneum
small bowel or omentum with any single lesion less
than 2.0 cm, non-involvement of retroperitoneal lymph
nodes
IIIC Gross tumour extension to upper abdominal peritoneum,
small bowel or omentum with any single lesion greater
than 2.0 cm and/or involved retroperitoneal lymph
nodes
IV Involvement beyond the peritoneal cavity (e.g. distand
nodes) or liver parenchyma (If pleural effusion,
cytology must be proved to be positive)
cases (40.9%) a stage I tumour was detected, in 20 cases
(17.4%) stage II, in 34 (29.6%) stage III, and in 14 (12.1%)
stage IV. Histologic grading revealed 23 GI (20.0%), 39 G2
(33.9%), and 53 G3 tumours (46.1%) (Table III).
Abdominal hysterectomy with bilateral salpingo-oophorec-
tomy, was performed on 49 (42.6%) patients. Twenty-one
(18.3%) women were subjected to an additional total resec-
tion of the omentum. In 25 cases (21.8%), hysterectomy with
bilateral salpingo-oophorectomy, and infracolic resection of
the omentum, together with pelvic lymphadenectomy was
applied. Twenty (17.3%) women had only one of the adnexa
removed and/or were subjected to laparatomy. Complete,
radical removal of the tumour was achieved in 82 (71.3%)
patients; in 19 (16.5%) women residual tumour tissue less
than 2 cm had to be left; in only 14 (12.2%) cases the
remaining tumour was larger than 2 cm. Ascites ofmore than
250 ml was found intraoperatively in 25 (21.8%) women; the
only 90 (78.3%) patients were free of ascites.
Histologic examination revealed 56 (48.6%) papillary, 19
(16.5%) serous, 19 (16.5%) solid, 10 (8.8%) medullary, and
six (5.2%) mucinous carcinomas. The samples of five (4.4%)
patients did not allow histologic classification (Table IV).
Patients were treated postoperatively either by irradiation
or chemotherapy. High-voltage radiotherapy was performed
on 40 (34.8%) women at a dosage of 4,500 to 5,000 rad to
standard pelvic fields. Forty-nine (42.6%) patients received
chemotherapy, the scheme varying from department to
department; in 13 cases the PAC-regime (Morris, 1990) (cis-
platin, endoxan and doxirubicin) was given; 14 patients
received cisplatin as single agent; five women were treated
with carboplatin; four patients received Epirubicin and
Endoxan in combination; 13 women were treated with a
combination of cisplatin and methotrexate.
Twenty-six (22.6%) women did not receive any adjuvant
therapy because their tumours were either stage Ia (n = 10)
or they had a performance status III-IV according to WHO.
In the latter cases all tumours were in stage IV (n = 16).
The clinical symptoms in our patients corresponded on the
whole to those described in the literature, e.g. abnormal
vaginal bleeding, whitish-clear discharge, undefined abdom-
inal pain or increase in abdominal circumference.
Median survival time for all stages was 30.7 months, with
an observation period of at least one and maximally 144
months. Patients with tumous in stages I and II (n = 67) had
a median survival time of 55.7 months (min= 1; max = 144).
Median survival in stages III and IV (n = 48) was about 20.8
months (min = 1; max = 77).
The 5-year survival in stages I and II was 50.8% compared
to about 13.6% in stages III and IV (Figure 1).
Patients with tumour of grading I or II showed a better
survival compared to tumour with grading III although this
failed to reach statistical significance (P= 0.09) (Figure 2).
Patients with papillary cancer had median survival of 42.7
months, compared with 29.1 months in serous, 11.4 months
Table III Distribution of staging and degree of differentiation in
Fallopian tube cancer (n = 115)
FIGO GJ G2 G3 n %
I 13 16 18 47 40.9
II 7 9 4 20 17.4
III 3 8 23 34 29.6
IV - 6 8 14 12.1
20.0% 33.9% 46.1% 115 100.0%
Table IV Distribution of staging and histological features (n = 110)
FIGO stage Serous Papillary Solid Medullary Mucinous
I 11 21 6 6 2
II 3 12 3 1 1
III 5 16 6 2 2
IV - 7 4 1 1
n 19 56 19 10 6
% 16.5 48.6 16.5 8.8 5.2PRIMARY CARCINOMA OF THE FALLOPIAN TUBE 607
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Figure 1 Fallopian tube carcinoma.
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Figure 2 Fallopian tube carcinoma.
in mucinous, 40.7 in solid and 43.0 months in medullary
cancers. However, statistical analysis did not reveal any
significant difference (P = 0.996).
Since ascites is accepted as a well established prognostic
factor for ovarian cancer, its influence on survival was ana-
lysed, but did not reveal any impact on the outcome
(P = 0.2), probably due to the rare incidence of ascites on the
whole (21.7%) in stages III and IV only (Anonymous, 1981;
Berek et al., 1983).
The presence of residual tumour - also a prognosticator
for ovarian cancer - was also detected in stages III and IV
only (Anonymous, 1981; Berek et al., 1983). Even in advanc-
ed disease patients with residual tumour less than 2 cm had a
significantly better outcome compared to women with a
larger remaining mass (P = 0.03) (Figure 3).
On multivariate analysis, the most powerful predictor of
outcome in women with tubarian cancer was the FIGO-stage
(the population dichotomised for stage I + II vs III + IV)
(P
= 0.003). The only factor that added significantly to the
predictive power of the FIGO-stage was the residual tumour
(<2 cm vs >2 cm) (P = 0.02). Histologic grading failed to
reach any significance (P = 0.344).
Discussion
Primary cancer of the Fallopian tube is so rare that data
from single institutions cannot lead to any substantial conc-
lusions regarding therapy or prognosis. Worldwide, about
1,500 cases have been reported in the literature up to now,
with hardly more than a 100 cases per study (Table V).
A retrospective evaluation of multi-centre data was under-
taken covering a period of 12 years. Our results, as fo age,
and distribution of stages, are comparable to those o0 other
authors (Pfleiderer, 1984; Bohme et al., 1992; Kubista &
Kupka, 1977; Jones, 1965; Denham & MacLennan, 1984;
McMurray et al., 1986).
In the past, several authors tried to describe factors predis-
posing for a cancer of the Fallopian tube, by analysing
factors like menarche, menopause, parity and race (Engeler
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Figure 3 Fallopian tube carcinoma.
Table V
Dodson et al.
Schiller & Silverberg
Kubista & Kupka
Benedet et al.
Engeler et al.
Raju et al.
Tamini & Figge
Roberts & Lifshitz
Denham & MacLennan
Eddy et al.
McMurray et al.
Podratz et al.
Pfeiffer et al.
Morris et al.
Pakisch et al.
Bohme et al.
Year
1970
1971
1977
1977
1981
1981
1981
1982
1984
1984
1986
1986
1988
1990
1990
1992
n
10
76
31
42
37
22
15
102
40
71
40
47
52
18
33
17
et al., 1981; Pfeiffer et al., 1989; Bohme et al., 1992; Kubista
& Kupka, 1977; Eddy et al., 1984). The results, in most cases
obtained from small patient-populations, were too hetero-
genous to be reliable. Neither did studies on symptoms con-
tribute any further information for early diagnosis of this
disease (B6hme et al., 1992; Kubista & Kupka, 1977; Benedet
& White, 1981; Schiller & Silverberg, 1971; Roberts & Lif-
shitz, 1982).
Even though cancer of the Fallopian tube and of the
ovaries are histologically graded in one class, due to the same
origin from one germinal epithelium (Pfleiderer, 1984; Bohme
et al., 1992; Kubista & Kupka, 1977), there exist differences
between the two entities: first, in most cases cancer of the
Fallopian tube is diagnosed at an earlier stage than the
ovarian cancer and patients are able to seek medical atten-
tion earlier. Another difference between tubal and ovarian
cancer is that distant metastasis is relatively more important
as site of failure than in ovarian cancer.
McMurray reports that almost half of the recurrences
presented outside the peritoneal cavity, although usually in
association with intraperitoneal metastases (McMurray,
1986).
The reason for the earlier diagnosis of the carcinoma of
the Fallopian tube may be due to the painful tension in the
tubes, and to the abnormal discharge of serous fluid which
occurs frequently. An occlusion of the abdominal ostium of
the uterine tube in some patients may be the cause for these
phenomena (Benedet & White, 1981; Denham & McLennan,
1984).
It might be possible that this could lead to a delay in
lymphogenous and/or continuous growth of the tumour. This
could explain the higher incidence of prognostically more
favourable, early stages compared to ovarian cancer. Green
and Scully in 1962 reported on five patients who survived in
their series of 18 cases, and where the lateral ostium tubae
was occluded.
Histologically, the tumour is presented as adenocarcinoma
of various types (Pfleiderer, 1984; Eddy et al., 1984). In our
collective, papillary (48.6%) and serous (16.5%) adeno-
matous structures were predominant, while in relation to that
other manifestations like solid, medullary, and mucinous
structures were less frequent.
Highly differentiated cells were found in 46.1% of the
patients, and such of medium and low degree of different-
iation were present in only 33.9% and 20.0% of the cases
respectively. These results are comparable to those of
McMurray (1986); (GI = 39%, G2 = 20%, G3 = 43%) and
other authors (Pfeiffer, 1989; Benedet & White, 1981; Den-
ham & McLennan, 1984).
On the whole, better differentiated tumours, showed a
trend to a more favourable outcome, compared with G3
tumours (Figure 2). However, this influence did not reach
significance, neither in univariate nor multivariate analysis.
Contrary to this finding, a residual tumour mass less than
2 cm in patients with advanced disease (stage III and IV) had
a positive independent impact on survival compared to
patients with a bigger residual tumour mass (Figure 3).
On the other hand ascites - a strong prognosticator in
ovarian cancer (Anonymous, 1981; Berek et al., 1983) - was
found in only 21.7% of the women of stage III and IV and -
contrary to ovarian cancer - did not show any negative
influence on survival in patients with cancer of the Fallopian
tube.
Since patients with FIGO-stage I did not differ statistically
from patients with stage II in terms of survival (data not
shown) these two populations were grouped together in order
to reach a larger sample size (Table IV). Patients with stage
III and IV were also analysed as one group with advanced
disease.
Statistical evaluation showed a significantly (P = 0.0001)
higher number of cases in stages I and II (n = 67 or 58.3%)
than in stages III and IV (n = 48 or 41.7%) compared to
ovarian cancer (Sevelda et al., 1991).
The 5-year survival rate of all our patients was 36.5%. In
stages I and II 50.8% compared to 13.6% in stages III and
IV. This is comparable to that reported by other authors
(Bohme et al., 1992; Pfeiffer, 1989; Benedet & White, 1981;
Eddy et al., 1984; Podratz et al., 1986; Pakisch et al., 1990).
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On the whole, staging according to the modified FIGO-
system had the strongest influence on survival, univariate as
well as multivariate analysis.
In the majority of the cases, the above mentioned early
diagnosis allows a radical operative stabilisation (Engeler et
al., 1981). Ninety-five women in our series underwent radical
hysterectomy including the adnexa, and/or total resection of
the omentum, or lymphadenectomy respectively. Surgeons
succeeded in complete tumour removal in 82 cases (71.3%);
in 33 cases, which were all in stages III and IV, some residual
tumour had to be left.
As better outcome is invariably linked to early diagnosis,
the advantage of early detection should not be lost by less
radical surgery. Surgical intervention should be as complete
as possible, corresponding to the guidelines which are applied
in cases of ovarian cancer.
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